Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | DRD3 | P35462 | 6/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6608472 | 0.99 | LMNA (0.44) | LMNAKMT2AMAPK1EGFRMAPT | |
| SCHEMBL4985496 | 0.84 | TDP1 (0.46) | LMNAKMT2AMAPK1EGFRMAPT | |
| SCHEMBL4987894 | 0.79 | HTR1B (0.43) | LMNAKMT2AMAPK1EGFRMAPT | |
| SCHEMBL14370221 | 0.78 | HTR1B (0.57) | KMT2AMAPTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL14264000 | 0.78 | HTR1B (0.57) | KMT2AMAPTSMN1; SMN2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL6992659 | 0.78 | HTR1B (0.43) | LMNAKMT2AMAPK1EGFRMAPT | |
| SCHEMBL10522546 | 0.74 | KMT2A (0.52) | LMNAKMT2AMAPK1EGFRMAPT | |
| SCHEMBL4732706 | 0.71 | SMN1; SMN2 (0.46) | LMNAKMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL8202534 | 0.71 | SMN1; SMN2 (0.46) | LMNAKMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL27584424 | 0.71 | DRD3 (0.38) | LMNAKMT2AMAPK1EGFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| CN-1821236-B | Therapeutic heterocyclic compounds | ASTRAZENECA AB | 2010-06-23 | — | — | CN | disclosed |
| CN-100509794-C | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2009-07-08 | — | — | CN | disclosed |
| CN-100460402-C | Therapeutic benzopyranone compounds used as intermediates. | ASTRAZENECA AB (SE) | 2009-02-11 | — | — | CN | disclosed |
| CN-100384833-C | Therapeutic chroman compounds | ASTRAZENECA AB (SE) | 2008-04-30 | — | — | CN | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| CN-1821236-A | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | CN | disclosed |
| US-20060178372-A1 | Therapeutic quinoline compounds | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| US-7045514-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| EP-1353914-A2 | THERAPEUTIC CHROMONE COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353915-A2 | THERAPEUTIC CHROMAN COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003037872-A1 | THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037871-A1 | THERAPEUTIC QUINOLONE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| US-20020113316-A1 | Semiconductor device and method of manufacturing the same | CONON SALES CO., LTD. | 2002-08-22 | — | — | US | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| EP-1217648-A2 | Method of manufacturing an interlayer dielectric layer with low dielectric constant | Canon Sales Co., Inc. (JP) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | LMNA 1891/4885KMT2A 2073/4885MAPK1 2684/4885 |
| US-20060178372-A1 | Therapeutic quinoline compounds | HTR1B, HTR3B, HTR1A | LMNA 1636/4885KMT2A 910/4885MAPK1 2839/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | LMNA 1808/4885KMT2A 1265/4885MAPK1 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.